In the last trading session, 1.39 million Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares changed hands as the company’s beta touched 0.07. With the company’s per share price at $1.22 changed hands at -$0.12 or -8.96% during last session, the market valuation stood at $140.39M. KPTI’s last price was a discount, traded about -299.18% off its 52-week high of $4.87. The share price had its 52-week low at $0.62, which suggests the last value was 49.18% up since then. When we look at Karyopharm Therapeutics Inc’s average trading volume, we note the 3-month average coming to 1.74 million.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information
Instantly KPTI was in red as seen at the end of in last trading. With action -10.29%, the performance over the past five days has been red. The drop to weekly highs of 1.4148 subtracted -8.96% to the stock’s daily price. The company’s shares are showing year-to-date upside of 41.04%, with the 5-day performance at -10.29% in the red. However, in the 30-day time frame, Karyopharm Therapeutics Inc (NASDAQ:KPTI) is -14.08% down.
Karyopharm Therapeutics Inc (KPTI) estimates and forecasts
Data shows that the Karyopharm Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -3.17% over the past 6 months, a 4.80% in annual growth rate that is considerably lower than the industry average of 9.40%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Karyopharm Therapeutics Inc will fall -10.00%, while the growth in revenue is estimated to hit -6.90% for the next quarter. Year-over-year growth is forecast to reach 0.30% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $34.47 million. 6 analysts are of the opinion that Karyopharm Therapeutics Inc’s revenue for the quarter ending Jun 2024 will be $36.42 million. The company’s revenue for the corresponding quarters a year ago was $36.6 million and $37.58 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -5.80%. The estimates for the next quarter sales put growth at -3.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 16.79%. The 2024 estimates are for Karyopharm Therapeutics Inc earnings to increase by 1.62%.
